相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Jack P. Gleeson et al.
CLINICAL CANCER RESEARCH (2021)
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.
Scott S. Tykodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K. Pal et al.
LANCET (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
Thomas E. Hutson et al.
EUROPEAN UROLOGY (2021)
Phase II study of nivolumab and salvage nivolumab plus ipilimumab in treatment-naive patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A. McGregor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
Nicholas J. Vogelzang et al.
CLINICAL GENITOURINARY CANCER (2020)
Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
Ramaprasad Srinivasan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study
B. A. McGregor et al.
ANNALS OF ONCOLOGY (2020)
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R. Feldman et al.
CANCER (2020)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Christopher J. Ricketts et al.
CELL REPORTS (2018)
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Vadim S. Koshkin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2016)
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Martin H. Voss et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Andrew J. Armstrong et al.
LANCET ONCOLOGY (2016)
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets
Ying-Bei Chen et al.
NATURE COMMUNICATIONS (2016)
Current and future strategies in nonclear-cell metastatic renal cell carcinoma
Laurence Albiges et al.
CURRENT OPINION IN UROLOGY (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
Y. Koh et al.
ANNALS OF ONCOLOGY (2013)
A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2012)
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
Ana M. Molina et al.
INVESTIGATIONAL NEW DRUGS (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
